| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Colin Walsh, Matthew Baker |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 10.50p |
| Change Today | -0.25p |
| % Change | -2.33 % |
| 52 Week High | 19.25 |
| 52 Week Low | 8.75 |
| Volume | 25,752 |
| Shares Issued | 125.16m |
| Market Cap | £13.14m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 12:24 | 13,673 @ 10.10p |
| 10:33 | 6,844 @ 10.90p |
| 10:06 | 2,518 @ 10.21p |
| 08:27 | 2,257 @ 10.90p |
| 08:00 | 43 @ 11.50p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research